News|Articles|July 2, 2026

9 Endocrinology Headlines You Missed in Q2 2026

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

The second quarter of 2026 saw an influx of critical approvals from the US Food and Drug Administration (FDA) and a slew of major conferences including the American Diabetes Association (ADA) Scientific Sessions and the Endocrine Society (ENDO) Annual Meeting. Between inhaled insulin’s approval in pediatric patients and the topline efficacy of crinecerfont and retatrutide, all manner of drugs for type 1 diabetes (T1D), type 2 diabetes (T2D), and obesity received major updates.

Related to this article

November 12th, 2026

Diabetes Dialogue: Retatrutide Tops Semaglutide on A1C, Weight in T2D

TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.

November 12th, 2026

Diabetes Dialogue: CONNECT Trial Backs CGM in Non-Insulin Type 2 Diabetes

Tom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.

November 9th, 2026

The HCPFive: Top News for Healthcare Providers from the Week of 11/1

Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.

November 8th, 2026

SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG Spectrum

In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.

November 14th, 2026

Early Dupilumab in Pediatric EoE Tied to Lower Incident Asthma

Children with eosinophilic esophagitis treated with dupilumab before age 6 had about half the asthma incidence of matched untreated peers 3.5 years later.